Objective To analyze the fetal chromosomal karyotypes in prenatal diagnosis and the relationship between abnormal karyotypes and the indications of prenatal diagnosis. Methods Fetal chromosomal karyotypes were examined in 247 pregnant women (16 to 28 weeks' gestation) by amniocentesis. Results 14 abnormal chromosomal karyotypes were detected, the abnormal rate was 5.67%. Trisomy was the major abnormality, it was 7out of 14(50%), including 4 trisomy 21(42.86%)?2 trisomy 18(28.57%)?1 trisomy 13(14.28%).Balanced translocation was found in 6 fetuses, the frequency was 42.86%. In 18 pregnant women aged over 35 years,1 (5.56%) with trisomy 21 was detected, and 3 of trisomy 21 were in 229 pregnant women aged under 35 years (1.31%,P=0.235). 3 Trisomy were detected in 15 fetuses with ultrasonographic suspected abnormalities. Conclusions During the second trimester, in the pregnant women who had different indications for prenatal diagnosis, the rate of chromosomal abnormality was 5.67%. Trisomy was the most common abnormal karyotype. As one method of prenatal screening, ultrasound in the second trimester could increase the antenatal detection rate of fetal chromosomal abnormality.

The eco-environment in eastern part of Qinghai-Tibet plateau is a rather complicated complex. The plants species there are quite diverse. The plant resource from Polygonaceae family used in traditional Tibetan medicine is very rich according to preliminary investigation. There were 6 genera and 15 species. The flora and the medicine value of them were analyzed. And some suggestions about traditional Tibetan medicine plant resource exploitation and utilization were presented.
China ; Medicine, Tibetan Traditional ; methods ; Polygonaceae

Objective:To analyze of hot spots and cutting-edge dynamic researches on Traditional Chinese Medicine (TCM) treatment for atopic dermatitis (AD).Methods:The data were abstracted from the literature of AD from CNKI, VIP and WanFang database, during January 1st, 2000 to May 31st, 2021. CiteSpace was used to map Knowledge and visualize information on the law, research hot spots and trendency of TCM in the treatment of atopic dermatitis in recent 20 years.Results:A total of 478 articles were included, mainly from TCM colleges and universities in various provinces. Most of the cooperative institutions have subsidiary relationships, and there is less cross-agency and cross-regional cooperation. Hot research topics included AD, clinical research, TCM therapy, TCM syndrome differentiation, compound Glycyrrhizin, TCM external treatment, and TCM formular, forming 8 main clusters. Integrated Traditional Chinese and Western Medicine was the developing trend in the treatment of AD, and the establishment of animal models to evaluate the therapeutic effect is the research frontier.Conclusion:Knowledge mapping can show the evolution path, research hotspot and frontier of TCM in the treatment of AD, and lay a foundation for high quality researches.

Objective To investigate clinical and hematological features of myeloid neoplasms with eosinophilia and abnormal PDGFRA/B and the effect of imatinib. Methods The data of three eosinophilia patients with abnormal PDGFRA/B fusion gene in Changhai Hospital, the Second Military Medical University and 22 Chinese cases reported in Chinese medical journals were analyzed. Thirty-one cases of idiopathic hypereosinophilic syndrome from Changhai Hospital, the Second Military Medical University were used as the controls. Results Compared with idiopathic hypereosinophilic syndrome, no differences were found in age, percentage of bone marrow eosinophils and counts of platelets in peripheral blood in myeloid neoplasms with eosinophilia and abnormal PDGFRA/B (all P ＞0.05), but statistical differences were found in gender (χ2＝5.080, P ＝ 0.016), peripheral blood white blood cell count (t ＝ 4.908, P ＝ 0.001), eosinophilic granulocyte absolute value (χ2＝ 17.230, P ＝ 0.001) and hemoglobin concentration (t ＝ 2.770, P ＝ 0.013). The median follow-up time was 17 months (3-108 months) in 24 myeloid neoplasms patients with eosinophilia and abnormal PDGFRA/B from Chinese report. Complete hematopoietic remission (CHR) rate was 91.7 % (22/24) after the treatment of imatinib. The total complete molecular remission (CMR) rate was 75.0 % (18/24). The median time of remission was 3 months (1-8 months). CMR in patients with PDGFRA and with PDGFRB was 76.5 % (13/17) and 85.7 % (6/7), respectively. Only one patient (4.2 %) died of disease relapse. Conclusion Imatinib has a favorable effect on myeloid neoplasms with eosinophilia and abnormal PDGFRA/B featured by distinct hematologic and clinical manifestations.